Lonza(US:LZAGY)2022-01-26 16:49Financial Performance - Lonza achieved strong financial results in 2022, with sales of CHF 6.2 billion and a CER sales growth of 15.1%[3] - The company's CORE EBITDA reached CHF 2.0 billion, resulting in a margin of 32.1%[3] - A dividend increase of 17% to CHF 3.50 per share is proposed[3] - Lonza plans a share buyback of up to CHF 2 billion[3, 33] Divisional Performance - Biologics division experienced a sales growth of 21.7% and a CORE EBITDA margin of 37.5%[23] - Small Molecules division saw a sales growth of 5.9% and a CORE EBITDA margin of 30.3%[23] - Cell & Gene division's sales grew by 13.6%, with a CORE EBITDA margin of 16.7%[23] - Capsules & Health Ingredients (CHI) division had a sales growth of 5.9% and a CORE EBITDA margin of 33.0%[23] Investments and Outlook - CAPEX reached 30% of sales in 2022, reflecting continued growth investment[3] - Lonza anticipates a high single-digit CER sales growth and a CORE EBITDA margin of 30-31% for 2023[3, 55] - The company confirms its Mid-Term Guidance for 2024, projecting low teens CER sales CAGR and a CORE EBITDA margin of approximately 33-35%[3, 56]